- Home
- OCEAW vs EHC Comparison
OCEAW vs EHC Comparison
Compare OCEAW & EHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCEAW
- EHC
- Stock Information
- Founded
- OCEAW N/A
- EHC 1983
- Country
- OCEAW United States
- EHC United States
- Employees
- OCEAW 7
- EHC N/A
- Industry
- OCEAW Biotechnology: Pharmaceutical Preparations
- EHC Hospital/Nursing Management
- Sector
- OCEAW Health Care
- EHC Health Care
- Exchange
- OCEAW Nasdaq
- EHC Nasdaq
- Market Cap
- OCEAW N/A
- EHC N/A
- IPO Year
- OCEAW 2021
- EHC 1986
- Fundamental
- Price
- OCEAW $0.02
- EHC $103.35
- Analyst Decision
- OCEAW
- EHC Strong Buy
- Analyst Count
- OCEAW 0
- EHC 8
- Target Price
- OCEAW N/A
- EHC $107.38
- AVG Volume (30 Days)
- OCEAW N/A
- EHC 916.8K
- Earning Date
- OCEAW N/A
- EHC 04-24-2025
- Dividend Yield
- OCEAW N/A
- EHC 0.66%
- EPS Growth
- OCEAW N/A
- EHC 28.32
- EPS
- OCEAW N/A
- EHC 4.46
- Revenue
- OCEAW N/A
- EHC $5,373,200,000.00
- Revenue This Year
- OCEAW N/A
- EHC $10.10
- Revenue Next Year
- OCEAW N/A
- EHC $8.67
- P/E Ratio
- OCEAW N/A
- EHC $23.04
- Revenue Growth
- OCEAW N/A
- EHC 11.91
- 52 Week Low
- OCEAW N/A
- EHC $78.53
- 52 Week High
- OCEAW N/A
- EHC $104.55
- Technical
- Relative Strength Index (RSI)
- OCEAW N/A
- EHC 58.72
- Support Level
- OCEAW N/A
- EHC $101.68
- Resistance Level
- OCEAW N/A
- EHC $104.55
- Average True Range (ATR)
- OCEAW 0.00
- EHC 3.41
- MACD
- OCEAW 0.00
- EHC 0.28
- Stochastic Oscillator
- OCEAW 0.00
- EHC 89.69
About OCEAW Ocean Biomediacal Inc.
Ocean Biomedical Inc is a biopharmaceutical company that is focused on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases. The company is developing an antibody therapeutic product candidate inhibiting Chi3l1, and a bi-specific antibody product candidate inhibiting Chi3l1 plus PD-1 and CTLA-4 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome.